drugset
drugset / Trial / NCT05109390

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390 ↗

Phase 1 Completed 72 enrolled Alexion Pharmaceuticals, Inc. Achillion, a wholly owned subsidiary of Alexion · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in healthy adult participants.

Timeline

Start
2018-07-27
Primary completion
2018-10-17
Completion
2018-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Aluminum hydroxide Unknown 200 mg Oral
Subject Calcium carbonate Other / unclassified 1 g Oral
Subject Cyclosporine Peptide 300 mg Oral
Subject Danicopan Small molecule 200 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral
Subject Simethicone Other / unclassified 25 mg Oral
Subject Tacrolimus Small molecule 2 mg Oral
Subject magnesium hydroxide Unknown 200 mg Oral

Indications

No indication recorded.